metabolic dysfunction-associated steatotic liver disease (MASLD)F2/F3 liver fibrosisUS Food and Drug Administrationresmetirom
…etirom by the US Food and Drug Administration, the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) has potentially entered a new era, requiring a comprehensive un…